US 12,331,300 B2
Recombinant of hydrogenophilus bacterium with enhanced ability to produce valine
Hideaki Yukawa, Tokyo (JP); and Naoto Ohtani, Tokyo (JP)
Assigned to Utilization of Carbon Dioxide Institute Co., Ltd., Tokyo (JP)
Appl. No. 17/292,870
Filed by Utilization of Carbon Dioxide Institute Co., Ltd., Tokyo (JP)
PCT Filed Dec. 12, 2018, PCT No. PCT/JP2018/045781
§ 371(c)(1), (2) Date May 11, 2021,
PCT Pub. No. WO2020/121462, PCT Pub. Date Jun. 18, 2020.
Prior Publication US 2021/0403927 A1, Dec. 30, 2021
Int. Cl. C12N 15/70 (2006.01); C12N 1/20 (2006.01); C12N 9/10 (2006.01); C12N 15/74 (2006.01); C12P 13/08 (2006.01)
CPC C12N 15/74 (2013.01) [C12N 1/20 (2013.01); C12N 9/1022 (2013.01); C12P 13/08 (2013.01); C12Y 202/01006 (2013.01)] 15 Claims
 
1. A mutant acetolactate synthase III small subunit gene comprising a first mutant base sequence including SEQ ID NO: 2 in which at least one mutation selected from the group consisting of the following (i) to (p) is present in SEQ ID NO: 2
(i) a substitution of AAC at base Nos. 31 to 33 with GAT, GAC, CAT, CAC, GCT, GCC, GCA, or GCG;
(j) a substitution of GGC at base Nos. 40 to 42 with GAT, GAC, GCT, GCC, GCA, or GCG;
(k) a substitution of TCG at base Nos. 49 to 51 with TTT or TTC;
(l) a substitution of AAC at base Nos. 85 to 87 with AAA, AAG, TAT, TAC, GAT, GAC, CAT, or CAC;
(m) a substitution of ACC at base Nos. 100 to 102 with ATT, ATC, or ATA;
(n) a substitution of GCA at base Nos. 106 to 108 with GTT, GTC, GTA, or GTG;
(o) a substitution of CGC at base Nos. 250 to 252 with TAA, TAG, or TGA; and
(p) a substitution of CTC at base Nos. 391 to 393 with CGT, CGC, CGA, CGG, AGA, or AGG; or
a second mutation base sequence having 90% or more identity to the first mutant base sequence, provided that said at least one mutation is present in the second mutant base sequence.